NeuroBo Pharmaceuticals Inc (NRBO)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading NeuroBo Pharmaceuticals Inc chart...

About the Company

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.

Exchange

NASDAQ

$M

Total Revenue

9

Employees

$20M

Market Capitalization

-3.68

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NRBO News

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

23h ago, source:

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, ...

Ad Campaign for Weight-Loss Drugs Reinforces Proper Use

3h ago, source: Medscape

Eli Lilly and Company, which manufactures one of the new weight-loss drugs, has launched an advertising campaign reinforcing ...

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

10d ago, source: Business Insider

PRISM MarketView takes a closer look at five of our top picks for delivering the next potential treatments for the liver ...

Tonix picks CMOs for potential launch of fibromyalgia drug

on MSN ago, source:

Tonix (TNXP) said it has selected two CMOs as suppliers for the potential US launch of its non-opioid pain reliever Tonmya ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript

1d ago, source: InvestingChannel on MSN

March 26, 2024 Biora Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...

Metagenomi, Inc.: Strong Buy Rating on Robust Hemophilia Program and Strategic Partnerships

1d ago, source: Business Insider

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), with ... moves made by Metagenomi in partnership with Ionis ...

Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know

3d ago, source: Zacks.com on MSN

Biogen Inc. (BIIB) closed at $216.69 in the latest trading session, marking a -0.65% move from the prior day. This change lagged the S&P 500's daily loss of 0.31%. Elsewhere, the Dow lost 0.41%, while ...

Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results

15d ago, source: Investor ideas

March 13, 2024 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com) Biotech Stock News Bites - Heron ...

NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

21h ago, source: Finanznachrichten

March 28, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...